You searched for: fins like tyrosine kinase 3 (Engelska - Estniska)

most tyrosine kinase
enamus türosiinkinaasi

most tyrosine kinase inhibitors
enamus türosiinkinaasi

osimertinib is a tyrosine kinase inhibitor (tki).
osimertiniib on türosiini kinaasi inhibiitor (tki).

pharmacotherapeutic group: protein-tyrosine kinase inhibitor, atc code:
farmakoterapeutiline grupp: proteiintürosiinkinaasi inhibiitor, atc kood:

iclusig belongs to a group of medicines called tyrosine kinase inhibitors.
iclusig kuulub ravimite rühma, mida nimetatakse türosiinkinaasi inhibiitoriteks.

the active substance in bosulif, bosutinib, is a tyrosine kinase inhibitor.
bosulifi toimeaine bosutiniib on türosiinkinaasiinhibiitor.

the active substance in palladia, toceranib, is a receptor tyrosine kinase inhibitor.
palladia toimeaine totseraniib on retseptori türosiinkinaasi inhibiitor.

the active substance in masivet, masitinib, is a protein-tyrosine kinase inhibitor.
masiveti toimeaine masitiniib on valgu türosiinkinaasi inhibiitor.

the active substance in imatinib teva, imatinib, is a protein-tyrosine kinase inhibitor.
imatinib teva toimeaine imatiniib on proteiintürosiinkinaasiinhibiitor.

the presence of a mutated tyrosine kinase c-kit receptor must be confirmed prior to treatment.
muteerunud türosiinkinaasi c-kit retseptori olemasolu tuleb enne ravi kinnitada.

imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the
imatiniib on väikesemolekuliline proteiintürosiinkinaasi inhibiitor, mis pärsib tugevalt nii bcr-abl

(ph+ cml) previously treated with one or more tyrosine kinase inhibitor(s) and for
patsientidel, keda varem raviti ühe või enama türosiini kinaasi inhibiitoriga ja kelle

however, in preclinical wound healing models egfr selective tyrosine kinase inhibitors were shown to retard wound healing.
ent prekliinilistes haavaparanemise mudeluuringutes oli egfr selektiivsel türosiinkinaasi inhibiitoritel haavaparanemist aeglustav toime.

ibrutinib is a potent, small-molecule inhibitor of bruton’s tyrosine kinase (btk).
ibrutiniib on tugevatoimeline väiksemolekuliline brutoni türosiinkinaasi (btk) inhibiitor.

the relationship, if any, between receptor tyrosine kinase (rtk) inhibition and cardiac function remains unclear.
seos, kui see üldse on olemas, retseptori türosiini kinaasi (rtk) inhibeerimise ja südamefunktsiooni vahel jääb selgusetuks.

the active substance in iclusig, ponatinib, belongs to a group of medicines called ‘tyrosine kinase inhibitors’.
iclusigi toimeaine ponatiniib kuulub türosiinkinaasiinhibiitorite ravimirühma.

bosulif was investigated in one main study involving 570 patients with ph+ cml who had previously been treated with at least one tyrosine kinase inhibitor.
bosulifi hinnati põhiuuringus, milles osales 570 philadelphia kromosoomiga kroonilise müeloidleukeemiaga patsienti, keda oli varem ravitud vähemalt ühe türosiinkinaasiinhibiitoriga.

imatinib is a protein kinase inhibitor which potently inhibits the bcr-abl tyrosine kinase at the in vitro, cellular and in vivo levels.
imatiniib on proteiini kinaasi inhibiitor, mis pärsib tugevalt bcr-abl türosiinkinaasi in vitro, rakulisel ja in vivo tasemel.

treatment of non-resectable dog mast cell tumours (grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor
kindlaks tehtud muteerunud c- kit türosiinkinaasi retseptoriga mitteresetseeritavate nuumrakuliste kasvajate (2. või 3. staadium) ravi koertel.

axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (vegfr)-1, vegfr-2 and vegfr-3.
aksitiniib on tugev selektiivne vaskulaarse endoteliaalse kasvufaktori retseptorite (vegfr)-1, vegfr-2 ja vegfr-3 türosiinkinaasi inhibiitor.